Business Wire

Communities, Businesses, and NGOs Unite to Tackle Water Challenges for World Water Day 2025

18.2.2025 11:00:00 CET | Business Wire | Press release

Share

Volunteers Invited to Join a Global Wave of Action to Expand Clean Water Access

With 2.2 billion people lacking safe water, communities, businesses, and NGOs are taking bold action this World Water Day to accelerate solutions. From March 17-22, thousands of volunteers worldwide will mobilize to improve water security—through cleanups, education programs, and projects expanding access to safe water, sanitation, and hygiene (WASH).

“Around the world, volunteers are driving meaningful progress toward providing clean water and sanitation for communities everywhere,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem, a leading global water technology company. “The Wave of Action is an opportunity to scale our impact on urgent water challenges and help communities become water-secure. We’ve seen what’s possible when people come together to take real action.”

For World Water Day 2025, Xylem and its partners welcome participants to get involved in making communities around the world more water-secure. Whether leading a cleanup, joining an educational event, or supporting WASH initiatives, volunteers will help build a more water-secure world.

A Wave of Action webinar on Thursday, Feb. 20, will feature global partners such as Mercy Corps, Engineers Without Borders USA, and Young Leaders from Manchester City’s Water Champions Project. Register for the webinar here.

Anyone can get involved by leading or joining a local volunteer effort. Free playbooks offer step-by-step guidance to help participants organize activities and track their impact. Visit Global Watermark Wave of Action to download playbooks, log your participation, and help activate a donation from Xylem to our nonprofit partners.

Since 2019, Xylem’s corporate social responsibility program, Watermark, has delivered WASH solutions to more than 16 million people, provided water education to over 12 million people, and responded to 154 water-related disasters.

Last year, alone, volunteers organized by Xylem:

  • Provided emergency clean water to 54,000 people in Brazil displaced by catastrophic floods, thanks to collaborations with Planet Water Foundation.
  • Assembled 2,000 water filters, supplying 20,000 people in crisis zones, including Ukraine, with safe drinking water.
  • Funded WASH education programs for children affected by the Morocco earthquake.
  • Mobilized more than 3,000 participants to support schools facing water contamination; and raised $200,000 for water infrastructure projects.

In all, Xylem employees and partners dedicated more than 220,000 volunteer hours in 2024 through 1,380 nonprofit partnerships in 55 countries.

About Xylem

Xylem (XYL) is a Fortune 500 global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered revenue of $8.6 billion in 2024, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and Let’s Solve Water.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218396410/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye